CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25833307.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2553.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The research article by Prewett and colleagues, published in the May 1, 2002, issue of Clinical Cancer Research, provided important translational data that extended earlier preclinical and clinical studies with the human-murine chimeric anti-EGFR monoclonal antibody C225. Subsequent clinical trials with C225 led to the demonstration of its efficacy in combination with irinotecan and regulatory approval for the treatment of metastatic colorectal cancer.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Cetuximab
- Colorectal Neoplasms
- Medical Oncology